Anti-ACE2 Antibody (PE), Mouse Monoclonal sinobiological 10108-MM37-P
| Catalog No. | Size | Price (USD) |
| 10108-MM37-P-25 | 25 Tests | $148.11 |
| 10108-MM37-P-100 | 100 Tests | $296.22 |
| Catalog No. | Size | Price (USD) |
| 10108-MM37-P-25 | 25 Tests | $148.11 |
| 10108-MM37-P-100 | 100 Tests | $296.22 |
General Information
| Product name | Anti-ACE2 Antibody (PE), Mouse Monoclonal |
| Validated applications | FCM (FAQ Protocol) |
| Species reactivity | Reacts with: Human |
| Specificity | Human ACE2 |
| Immunogen | Recombinant Human ACE2 Protein (Catalog#10108-H08H) |
| Preparation | This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human ACE2 (rh ACE2; Catalog#10108-H08H; NP_068576.1; Met1-Ser740) and conjugated with PE under optimum conditions, the unreacted PE was removed. |
| Source | Monoclonal Mouse IgG1 Clone #37 |
| Purification | Protein A |
| Formulation | PBS solution containing 0.5% BSA and 0.03%ProClin300 |
| Concentration | 5 μl/Test, 0.1 mg/ml |
| Conjugate | PE |
| Form | Liquid |
| Shipping | This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| Storage | This antibody can be stored at 2℃-8℃ for twelve months without detectable loss of activity. Protected from prolonged exposure to light. Do not freeze ! |
Synonyms: Anti-ACEH Antibody; Anti-UNQ868/PRO1885 Antibody
Image / Experimental Information
| Image 1 Description | Flow cytometric analysis of Human ACE2 expression on ACE2-transfected 293T cells. Cells were stained with PE-conjugated anti-Human ACE2. The fluorescence histograms were derived from gated events with the forward and side light-scatter characteristics of intact cells. |
| Image 1 Alt Text | Human ACE2 Flow Cytometry (FC) 30817 |
| Image 1 URL | Source image |
Background Information
| Full Name | angiotensin I converting enzyme 2 |
| Description | Angiotensin-converting enzyme 2 (ACE2), a first homolog of ACE, regulates the renin angiotensin system (RAS) by counterbalancing ACE activity. Accumulating evidence in recent years has demonstrated a physiological and pathological role of ACE2 in the cardiovascular, renal and respiratory systems. ACE2 also has an important role in blood pressure control. This enzyme, an homolog of ACE, hydrolyzes angiotensin (Ang) I to produce Ang-(1-9), which is subsequently converted into Ang-(1-7) by a neutral endopeptidase and ACE. ACE2 releases Ang-(1-7) more efficiently than its catalysis of Ang-(1-9) by cleavage of Pro(7)-Phe(8) bound in Ang II. Thus, the major biologically active product of ACE2 is Ang-(1-7), which is considered to be a beneficial peptide of the RAS cascade in the cardiovascular system. A physiological role for ACE2 has been implicated in hypertension, cardiac function, heart function and diabetes, and as a receptor of the severe acute respiratory syndrome coronavirus. In the acute respiratory distress syndrome (ARDS), ACE, AngII, and AT1R promote the disease pathogenesis, whereas ACE2 and the AT2R protect from ARDS. Importantly, ACE2 has been identified as a key SARS-coronavirus receptor and plays a protective role in severe acute respiratory syndrome (SARS) pathogenesis. Furthermore, the recent explosion of research into the ACE2 homolog, collectrin, has revealed a new physiological function of ACE2 as an amino acid transporter, which explains the pathogenic role of gene mutations in Hartnup disorder. This review summarizes and discusses the recently unveiled roles for ACE2 in disease pathogenesis. |
| References |
|
title: SARS-CoV-2 Omicron sublineages show comparable cell entry but differential neutralization by therapeutic antibodies.
authors: Prerna Arora; Lu Zhang; ...; Markus Hoffmann
journal: Cell host & microbe
date: 2022-08-15
pmid: 35588741
cited_by_count: 48
techniques: Centrifugation; Expressing; Incubation; Inhibition; Plasmid Preparation; Transfection
bioz_score: 90
title: Antibody Responses In Non-Severe SARS-CoV-2 Infections Are Driven By CD4+ T cells and Age
authors: Murrell Amelie E.; Eyoh Ewono; ...; Norton Elizabeth B.
journal: medRxiv
date: 2022-04-22
doi: 10.1101/2022.04.22.22274032
cited_by_count: 0
techniques: Binding Assay; Expressing; Flow Cytometry; Infection; Luciferase; Neutralization; Stable Transfection
bioz_score: 90